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Research

Dean’s Message

M

ore than 2,000 scientists
from around the world
– and counting – have
utilized a computer software
and database system created
and housed at the UConn
Health Center to construct
computational models of cells.
Called the Virtual Cell, it also
performs simulations to analyze
the results of those simulations
to better understand cell
physiology. In this issue, we
will introduce you to Dr. Leslie
Loew, director of the UConn
Health Center’s Richard D. Berlin
Center for Cell Analysis and
Modeling, and the impressive

work his multidisciplinary team
is producing.
Dr. Loew, together with
a cadre of elite researchers
from several other bioscience
departments, recently moved
into the new, state-of-the-art
Cell and Genome Sciences
Building, adjacent to our
campus. The building’s awardwinning design was created to
encourage cross-disciplinary
collaborations and innovations.
Of note, the building also
includes incubator space for
emerging bioscience industries
which was fully leased within
the first year of occupancy.

The Cell and Genome Sciences
Building was dedicated earlier
this year (see photo on back
page), heralding in a new era of
growth in bioscience research
and job creation. We look
forward to sharing updates
and exciting new advances in
future issues!
Sincerely,

Cato T. Laurencin, M.D., Ph.D.
Vice President for Health Affairs
Dean, UConn School of Medicine
laurencin@uchc.edu

UConn Cardiologists
Uncover New Heart
Attack Warning Sign

H

ealth Center cardiologists, led
by Bruce Liang, M.D., F.A.C.C.,
director of the Pat and Jim Calhoun
Cardiology Center, have identified a
protein fragment that when detected in
the blood can be a predictor of heart
attack. Their research was published
in a recent issue of the Journal of the
American College of Cardiology. It found
that heart attack patients had elevated
levels of the protein fragment known as
Caspase-3 p17 in their blood.

“We’ve discovered a new biomarker for
heart attack and showed that apoptosis
is a cause of heart muscle damage,”
Liang says. “The ability to see a heart
attack coming with a simple blood test
and to develop new therapies to block
apoptosis would enable us to get a head
start on treatment and preserve crucial
heart muscle and cardiac function.”
“This test can work in patients but
has not met regulatory requirements
for clinical application in patients
suspected of having a heart attack,”
Liang says. “If it is successfully applied
one day, it would mean another way to
diagnose heart attack and the possible
development of new treatments.”

Bruce Liang, M.D., F.A.C.C.

Co-investigators include Mariela
Agosto, M.D., Michael Azrin, M.D., and
Kanwar Singh, M.D., F.A.C.C., from the
UConn Health Center and Allan Jaffe,
M.D., from the Mayo Clinic and Mayo
Medical School in Rochester, Minn. n

Clinical Trials Favorable for Novel Breast Cancer Detection Device
Education

New Leader for
Graduate School

B

arbara E. Kream, Ph.D.,
has been appointed the
associate dean of the
Graduate School. A professor
of Medicine and Genetics and
Developmental Biology, she
holds a joint appointment as
professor in the Department of
Orthopaedic Surgery. Kream
has been active with student
training and mentoring and is
a long-standing member of the
Biomedical Science and Dental
Science Graduate faculty. She
currently is the director of the
M.D./Ph.D. program. n

UConn School of Medicine

The 19 th Century
Goes Digital

T

he Hartford Medical
Society Historical
Library at the UConn
Health Center has its
first five titles digitized
and available for viewing
through the Internet
Archive, a digital library
found at www.archive.org
that offers free access to
books and other materials.
Touching on a range of
unexpected topics, these
newly digitized titles from
the 19th century include
such peculiar titles as
Human Monstrosities,
Pathology of Drunkenness,
and Observations on the
Management of Madhouses.
To see the full list and access
the digitized volumes visit
http://uchc.libguides.com/
hms. n

A

novel imaging device developed at the University of
Connecticut is showing favorable results in an
expanded clinical trial and could
significantly reduce physicians’ reliance
on breast biopsies.
The device, which uses
ultrasound-guided diffuse optical
tomography (DOT) to locate
and analyze suspicious tumors in
breast tissue, was tested on 178
women over a four-year period
from 2004 to 2008. The study was
supported by the National Institutes
of Health and the Donaghue Medical
Research Foundation. Testing was
conducted among patients between the
ages of 21 and 89 at the UConn Health Center
and Hartford Hospital.
The study showed that the device had a reliability rate of 92
percent in terms of sensitivity and 93 percent in terms of specificity
when evaluating smaller cancers less than 2 centimeters in size. The
results of the study have been published in the journal Radiology,
published by the Radiological Society of North America.
“Based on our results, we believe DOT holds promise as
an adjunct to diagnostic mammography and ultrasound for
distinguishing early-stage invasive breast cancers from benign
lesions,” says Quing Zhu, Ph.D., a professor in the Department of
Electrical and Computer Engineering. Zhu has been working with

graduate students in the School of Engineering and Health Center
physicians over the past decade to refine and test the device.
“We expect this technology will be used to help radiologists
evaluate small- to intermediate-sized lesions that are harder
to diagnose with conventional imaging technologies,” Zhu
says. “We will not completely eliminate biopsies. No
modality is perfect. But we want to improve existing
imaging technology so a better diagnosis can be made.”
In the UConn study, women who had
suspicious lesions in their breasts were first analyzed
with DOT and then given a needle biopsy. The
results of each test were then correlated to judge the
sensitivity and specificity of the DOT. Zhu says the
DOT found both maximum and average total hemoglobin
levels were significantly higher in the malignant groups than
in the benign groups of tissue samples, proving the device’s
effectiveness. Laboratory examination of the tissue samples
revealed two in situ carcinomas, 35 carcinomas that measured less
than 2 centimeters, 24 carcinomas greater than 2 centimeters, and
114 benign lesions.
The DOT device has been patented. “The next step is to
develop multi-institution prospective clinical trials to further
evaluate the device’s effectiveness,” Zhu says. Collaborating with
Zhu on the study were Poornima Hegde, M.D., Mark Kane,
M.D., Susan Tannenbaum, M.D., Peter Deckers, M.D., and Scott
Kurtzman, M.D., from the UConn Health Center and Edward
Cronin, M.D., Andrew Ricci Jr., M.D., and Patricia DeFusco,
M.D., from Hartford Hospital. n
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Erick Avelar, M.D., (left) and a Health Center
PROMISE co-investigator Clifford Yang, M.D.

Research

Uncovering the Mysteries
of Human Cells
“Our Center is unique in that
we have chemists, physicists,
mathematicians, biologists,
and computer scientists all
working together.”
				

UConn School of Medicine

Les Loew, Ph.D., director of CCAM

E

ach of the 100 trillion cells in the human body is a tiny parcel
of water and chemicals containing the entire human genome
– all of the DNA that an individual possesses. For Leslie
Loew, Ph.D., and his team of researchers, uncovering the mysteries
of these cells and how they behave in the body is a mission, a
fascination, a pursuit that can lead to a better understanding of
diseases and how best to treat them.
Loew, a professor of cell biology as well as computer science
and engineering, is the director of the UConn Health Center’s
Richard D. Berlin Center for Cell Analysis and Modeling (CCAM).
Loew and fellow researchers at CCAM are developing new
approaches to determine how cells work, interact, and respond –
and how to organize this data so it can be applied to human health.
CCAM integrates state-of-the-art microscope technologies with
computational tools that produce realistic models of cell dynamics.
The innovative work performed at CCAM has received worldwide
attention and millions in annual grant support since the Center
was established in 1994.

w

Bringing together biomedical researchers
from various disciplines, CCAM provides a
setting that supports and reinforces the value
of collaboration. “Our Center is unique in that
we have chemists, physicists, mathematicians,
biologists, and computer scientists all
working together,” Loew says. “We were far
ahead of our time when we started these
interdisciplinary groups.”
It is also the home of the Virtual Cell,
a computerized environment that allows
scientists to simulate the inner workings of
cells. With the Virtual Cell, investigators can
build intricate models using a web-based
interface in order to evaluate hypotheses,
interpret data, or probe the predicted behavior
of complex systems.
Designated and funded as a National
Resource by the National Institutes of Health
(NIH), the Virtual Cell is available for free via
the Internet as a tool for scientists and other
members of the scientific community.
“More than 2,000 labs around the world
are using the Virtual Cell,” Loew says. “The
NIH grant mandates that we continue building
software to support it and to make sure there is
access to it.”

Research in Progress

L

oew’s team at CCAM is currently
partnering on a project with the Mount
Sinai School of Medicine and Columbia
University to determine how human kidney
cells are regulated to produce the delicate
filtration system that allows the kidney to
function. The project has been awarded a
five-year, $6 million grant from the NIH’s
Transformative Research Project Program,
which supports innovative research with the
potential for major impact on human health.

In this study, the Virtual Cell is being used
to develop computational models of how
cells interact within kidney tissues.
Ultimately, its results could aid scientists
in understanding disease processes and in
screening for new drugs.
Another example of current Virtual Cell
research is a study by M.D./Ph.D. candidate
Sherry-Ann Brown that examines the way
in which signals in the brain are transferred
across synapses and neurons. Genetic defects
in these biochemical pathways are linked
to ataxia, which impacts an individual’s
motor coordination, speech, handwriting,
and balance. Such research could lead to a
better understanding of brain cell function –
resulting in advances in prevention, diagnosis,
and treatment.
CCAM provides a vast array of laboratory
equipment that can be used for obtaining
experimental data needed to create and
enhance Virtual Cell models. Among CCAM’s
$8 million in major equipment are confocal
and laser optical microscopes, multiprocessor
computers, and spectrometers that use light to
study matter.
The Center recently moved to the new
Cell and Genome Sciences Building, which
was designed to promote interdisciplinary
research in a wide range of projects. In
addition to CCAM, the building also
houses the UConn Stem Cell Institute, the
Department of Genetics and Developmental
Biology, and UConn’s Office of Technology
Commercialization (including the Technology
Incubation Program – UConn’s business
incubator), enhancing the University’s role as
a leader in innovative research and technology
in these areas.
CCAM, and especially the Virtual Cell,
is the culmination of decades of work for
Loew, who began his career in an academic
chemistry department. “Some of
the technology I was developing
could be applied to asking
questions about how cells
behave,” he says of his research.
“It soon became clear to me
that I was only going to enjoy
developing these tools if I could
use them myself.” n
Ann Cowan, Ph.D., deputy director of CCAM.

x

Cardiac Imaging
Study Shows
Promise

T

he Pat and Jim Calhoun
Cardiology Center has been
invited to be a test site for a
groundbreaking clinical trial.
The National Institutes of
Health is studying the use of
cardiac imaging to diagnose
problems associated with chest
pain, the most common clinical
cardiology problem.
The PROspective Multicenter
Imaging Study for the Evaluation
of Chest Pain, or PROMISE, is
the first randomized imaging
trial in the history of cardiology.
It seeks to enroll 10,000
patients at more than 200 sites
throughout the U.S. The UConn
Health Center was the first site
in Connecticut to join the study,
with Erick Avelar, M.D., director
of noninvasive cardiac imaging,
serving as principal investigator.
“Computed tomography of
the coronary artery, also known
as a cardiac CT, is hypothesized
to yield better results than
functional testing such as an
EKG or stress test, but it is not
the current standard of care
and generally not covered by
insurance,” Avelar says.
The targeted study
population consists of chest
pain patients with low to
intermediate probability of
significant obstructive coronary
artery disease, including men 55
and older and women 65 and
older. Men as young as 45 and
women as young as 50 also may
be eligible, depending on their
individual risk factors. n
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Gifts

Honors

UConn Health Center Celebrates 50th
Anniversary with White Coat Gala

P

art of the yearlong celebration of the UConn Health
Center’s founding included the festive White Coat gala
this spring.
With more than 800 people in attendance, funds were
raised to support faculty and researchers throughout the
institution. During the event, three leaders who have played
vital roles in the history of the Health Center were honored:
Marja Hurley, M.D., is an internationally prominent
molecular biologist and endocrinologist who has served the
Health Center for 25 years. She directs the Health Career
Opportunity Programs, and is currently serving as the medical
school’s interim senior associate dean for education.
Ravindra Nanda, B.D.S, M.D.S., Ph.D., is a renowned
leader in orthodontics who joined the Health Center in 1972.
He is the UConn Orthodontic Alumni/Ravi Nanda Chair in
Orthodontics and head of the Division of Orthodontics and
the Department of Craniofacial Sciences.
Basketball Hall of Fame Coach Jim Calhoun is a longstanding and generous donor. All told, he and his wife Pat have
helped raise nearly $3 million to support the Health Center’s
cancer and cardiology programs. n

Front row, left to right: Title Sponsor Richard Lublin; Ray Neag; Carole Neag; Honoree
Dr. Marja Hurley; Pat Calhoun; Honoree Dr. Ravi Nanda; Catherine Nanda.
Back row, left to right: Dental School Dean Dr. Monty MacNeil; Lee MacNeil; Honoree
Jim Calhoun; Vice President for Health Affairs Dr. Cato T. Laurencin; Cynthia Laurencin;
John Hurley.

Gift to Support Stem
Cell Research

I

n appreciation for committing
$700,000 to support stem cell research,
the Edmund and Arlene Grossman
Auditorium was dedicated in their honor
during the Cell and Genome Sciences
Inaugural Symposium this past December.
“The University of Connecticut has been a
national leader in the area of stem cell research,
and the generous support of Edmund and Arlene
Grossman will help us immeasurably to expand our work
in this vital area,” says University of Connecticut interim
president Philip E. Austin. “Our faculty’s research in this field
is emblematic of the University’s role in expanding the frontiers
of knowledge in areas of critical importance to the people of
Connecticut and far beyond.”
The Grossmans, both cancer survivors, want to support
research that has the greatest potential to treat and cure diseases
such as Parkinson’s and Alzheimer’s, which have affected close
friends of theirs, as well as cancer.
“This is such an incredible time in medical research that
it behooves those of us who can to provide for the gains. The

UConn School of Medicine

implications are mind-boggling. The good that could be done
with stem cell research far outstrips anything else we could do
to help mankind,” says Mr. Grossman.
“Ed and Arlene Grossman share our vision and believe in
our promise to be a world leader in stem cell research. Their
support will help us attract preeminent faculty and translate
discoveries made in the lab into new therapies and cures,” says
Marc Lalande, Ph.D., director of the Stem Cell Institute and
senior associate dean for research planning and coordination at
the UConn Health Center. n

Inside the Grossman Auditorium.

y

UConn Cardiologist 1st in New England
with New Treatment

Cancer Center Director Appointed

P

K

ramod K. Srivastava, Ph.D.,
M.D., an accomplished
leader in basic and
translational research, has
been named the new director
of the Carole and Ray Neag
Comprehensive Cancer Center.
Srivastava is a professor and
interim chair of the Department
of Immunology, director of the
Center for Immunotherapy of
Cancer and Infectious Diseases,
and part of the leadership team
of the Connecticut Institute
for Clinical and Translational
Science. He holds the Physicians Health Services Chair in
Cancer Immunology.
He has earned international acclaim for his groundbreaking
work in the immunological function of heat shock proteins
and in cancer immunology, is widely published in scholarly
journals, and serves on editorial boards for several major
journals in immunology. n

anwar Singh,
M.D., F.A.C.C.,
an interventional
cardiologist in the Pat and
Jim Calhoun Cardiology
Center, is the first physician
in the region to take an
innovative, minimally
invasive approach to treating
peripheral arterial disease.
Using a new device
called the Wildcat catheter,
Singh was able to reopen a
completely blocked artery
Dr. Kanwar Singh shows cardiology nurse
in a patient’s leg through a
Cathy Ingriselli the Wildcat catheter.
2-millimeter skin incision.
Some blockages are
severe and difficult to pass through with traditional catheters,
forcing patients to undergo more invasive bypass surgery
and subjecting them to higher risks and prolonged recovery.
In those cases where the plaque deposits cannot be passed,
patients face an increased possibility of losing a limb to
amputation. This minimally invasive alternative to bypass
surgery enables patients to leave the hospital within hours
and return to normal activities within a few days.
“The Wildcat catheter was developed by Avinger, Inc.,
who approached us,” Singh says. “They know we are doing
truly advanced work here in vascular disease and wanted
to partner with us early in the rollout of this new device.
Amazingly, as advanced as the Wildcat catheter already is,
the future generations of this tool will incorporate a forwardlooking imaging component that may be the next quantum
leap in vascular disease, so it’s really exciting to be a part of
this program.” n

New Academic Chair Announced

R

oyce Mohan, Ph.D., a
scientist and educator
who specializes in tissue
repair of the eye, has joined
the UConn Health Center
as the John A. and Florence
Mattern Solomon Chair
in Vision Biology and Eye
Diseases.
Mohan, who has a Ph.D.
in biochemistry from Ohio
State University, was most recently an associate professor in
the Department of Ophthalmology and Visual Sciences at
the University of Kentucky. He won acclaim at Kentucky for
a discovery that holds the potential for new treatments for
diseases of the brain, spinal cord and eye.
Florence Solomon, one of the chair’s donors, suffers from
macular degeneration, a focus of Mohan’s research. Mohan,
mentored at Yale University in chemical genetics and inspired
by pioneer Judah Folkman of Harvard Medical School, brings
a distinctive mark to anti-angiogenesis and anti-fibrosis
therapeutic research. n
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UConn Health Center Celebrates 50th
Anniversary with White Coat Gala

P

art of the yearlong celebration of the UConn Health
Center’s founding included the festive White Coat gala
this spring.
With more than 800 people in attendance, funds were
raised to support faculty and researchers throughout the
institution. During the event, three leaders who have played
vital roles in the history of the Health Center were honored:
Marja Hurley, M.D., is an internationally prominent
molecular biologist and endocrinologist who has served the
Health Center for 25 years. She directs the Health Career
Opportunity Programs, and is currently serving as the medical
school’s interim senior associate dean for education.
Ravindra Nanda, B.D.S, M.D.S., Ph.D., is a renowned
leader in orthodontics who joined the Health Center in 1972.
He is the UConn Orthodontic Alumni/Ravi Nanda Chair in
Orthodontics and head of the Division of Orthodontics and
the Department of Craniofacial Sciences.
Basketball Hall of Fame Coach Jim Calhoun is a longstanding and generous donor. All told, he and his wife Pat have
helped raise nearly $3 million to support the Health Center’s
cancer and cardiology programs. n

Front row, left to right: Title Sponsor Richard Lublin; Ray Neag; Carole Neag; Honoree
Dr. Marja Hurley; Pat Calhoun; Honoree Dr. Ravi Nanda; Catherine Nanda.
Back row, left to right: Dental School Dean Dr. Monty MacNeil; Lee MacNeil; Honoree
Jim Calhoun; Vice President for Health Affairs Dr. Cato T. Laurencin; Cynthia Laurencin;
John Hurley.

Gift to Support Stem
Cell Research

I

n appreciation for committing
$700,000 to support stem cell research,
the Edmund and Arlene Grossman
Auditorium was dedicated in their honor
during the Cell and Genome Sciences
Inaugural Symposium this past December.
“The University of Connecticut has been a
national leader in the area of stem cell research,
and the generous support of Edmund and Arlene
Grossman will help us immeasurably to expand our work
in this vital area,” says University of Connecticut interim
president Philip E. Austin. “Our faculty’s research in this field
is emblematic of the University’s role in expanding the frontiers
of knowledge in areas of critical importance to the people of
Connecticut and far beyond.”
The Grossmans, both cancer survivors, want to support
research that has the greatest potential to treat and cure diseases
such as Parkinson’s and Alzheimer’s, which have affected close
friends of theirs, as well as cancer.
“This is such an incredible time in medical research that
it behooves those of us who can to provide for the gains. The

UConn School of Medicine

implications are mind-boggling. The good that could be done
with stem cell research far outstrips anything else we could do
to help mankind,” says Mr. Grossman.
“Ed and Arlene Grossman share our vision and believe in
our promise to be a world leader in stem cell research. Their
support will help us attract preeminent faculty and translate
discoveries made in the lab into new therapies and cures,” says
Marc Lalande, Ph.D., director of the Stem Cell Institute and
senior associate dean for research planning and coordination at
the UConn Health Center. n

Inside the Grossman Auditorium.
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UConn Cardiologist 1st in New England
with New Treatment

Cancer Center Director Appointed

P
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ramod K. Srivastava, Ph.D.,
M.D., an accomplished
leader in basic and
translational research, has
been named the new director
of the Carole and Ray Neag
Comprehensive Cancer Center.
Srivastava is a professor and
interim chair of the Department
of Immunology, director of the
Center for Immunotherapy of
Cancer and Infectious Diseases,
and part of the leadership team
of the Connecticut Institute
for Clinical and Translational
Science. He holds the Physicians Health Services Chair in
Cancer Immunology.
He has earned international acclaim for his groundbreaking
work in the immunological function of heat shock proteins
and in cancer immunology, is widely published in scholarly
journals, and serves on editorial boards for several major
journals in immunology. n

anwar Singh,
M.D., F.A.C.C.,
an interventional
cardiologist in the Pat and
Jim Calhoun Cardiology
Center, is the first physician
in the region to take an
innovative, minimally
invasive approach to treating
peripheral arterial disease.
Using a new device
called the Wildcat catheter,
Singh was able to reopen a
completely blocked artery
Dr. Kanwar Singh shows cardiology nurse
in a patient’s leg through a
Cathy Ingriselli the Wildcat catheter.
2-millimeter skin incision.
Some blockages are
severe and difficult to pass through with traditional catheters,
forcing patients to undergo more invasive bypass surgery
and subjecting them to higher risks and prolonged recovery.
In those cases where the plaque deposits cannot be passed,
patients face an increased possibility of losing a limb to
amputation. This minimally invasive alternative to bypass
surgery enables patients to leave the hospital within hours
and return to normal activities within a few days.
“The Wildcat catheter was developed by Avinger, Inc.,
who approached us,” Singh says. “They know we are doing
truly advanced work here in vascular disease and wanted
to partner with us early in the rollout of this new device.
Amazingly, as advanced as the Wildcat catheter already is,
the future generations of this tool will incorporate a forwardlooking imaging component that may be the next quantum
leap in vascular disease, so it’s really exciting to be a part of
this program.” n

New Academic Chair Announced

R

oyce Mohan, Ph.D., a
scientist and educator
who specializes in tissue
repair of the eye, has joined
the UConn Health Center
as the John A. and Florence
Mattern Solomon Chair
in Vision Biology and Eye
Diseases.
Mohan, who has a Ph.D.
in biochemistry from Ohio
State University, was most recently an associate professor in
the Department of Ophthalmology and Visual Sciences at
the University of Kentucky. He won acclaim at Kentucky for
a discovery that holds the potential for new treatments for
diseases of the brain, spinal cord and eye.
Florence Solomon, one of the chair’s donors, suffers from
macular degeneration, a focus of Mohan’s research. Mohan,
mentored at Yale University in chemical genetics and inspired
by pioneer Judah Folkman of Harvard Medical School, brings
a distinctive mark to anti-angiogenesis and anti-fibrosis
therapeutic research. n
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onnecticut Governor Dannel Malloy takes part in a ceremonial
ribbon cutting with elected officials, University trustees and
directors, and researchers at the newly renovated Cell and
Genome Sciences Building. Equipped with the latest technologies,
the nearly 120,000-square-foot research facility has united
University scientists in accelerating discoveries
that ultimately could lead to novel
therapies treating a broad
range of diseases.
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